➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Johnson and Johnson
Baxter
McKesson
Dow

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 10,485,797

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,485,797
Title:Treatment of pemphigus
Abstract: The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.
Inventor(s): Gourlay; Steven (San Francisco, CA)
Assignee: PRINCIPIA BIOPHARMA INC. (South San Francisco, CA)
Application Number:15/537,294
Patent Claims:see list of patent claims

Details for Patent 10,485,797

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX Orphan search
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 002 2009-10-26   Start Trial PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) 2034-12-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Boehringer Ingelheim
McKinsey
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.